drugset / Trial / NCT06680596
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
Phase 2
Enrolling by invitation
80 enrolled
UNICANCER
AstraZeneca · collabBreast Cancer Research Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
After an initial screening phase to identify patients with persistent blood circulating DNA tumors, patients will be enrolled in the treatment phase that was designed as an open-label, multicentre, phase II study, to test the efficacy of trastuzumab deruxtecan in terms of progression-free survival (PFS).
Timeline
- Start
- 2025-07-30
- Primary completion
- 2028-08-01
- Completion
- 2029-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab deruxtecan | Monoclonal antibody | 5.4 mg/kg | Intravenous |